+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ace-associated decline in muscarinic cholinergic receptor (MChR) mediated inhibition of cardiac β-adrenergic receptor linked adenylate cyclase (AC)



Ace-associated decline in muscarinic cholinergic receptor (MChR) mediated inhibition of cardiac β-adrenergic receptor linked adenylate cyclase (AC)



Journal of Molecular and Cellular Cardiology 18(Supp-S3): 51-51




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 061854669

Download citation: RISBibTeXText

DOI: 10.1016/s0022-2828(86)80182-1


Related references

Concanavalin A amplifies both beta-adrenergic and muscarinic cholinergic receptor-adenylate cyclase-linked pathways in cardiac myocytes. Journal of Clinical Investigation 88(3): 760-766, 1991

Autonomic interactions in the aging heart: age-associated decrease in muscarinic cholinergic receptor mediated inhibition of beta-adrenergic activation of adenylate cyclase. Mechanisms of Ageing and Development 34(3): 249-259, 1986

Muscarinic cholinergic receptor modulation of beta adrenergic receptor affinity for catecholamines and catecholamine stimulation of adenylate cyclase activity. Clinical Research 26(3): 486A, 1978

Effects of muscarinic cholinergic receptor agonists on beta adrenergic and histamine h 2 receptor stimulated adenylate cyclase activity in guinea pig myo cardium. Clinical Research 30(4): 816A, 1982

Muscarinic receptor binding and muscarinic receptor-mediated inhibition of adenylate cyclase in rat brain myelin. Journal of Neuroscience 7(12): 3869-3876, 1987

Muscarinic cholinergic agonists regulate beta adrenergic receptor and adenylate cyclase in ventricular myo cardium. Federation Proceedings 37(6): 1788, 1978

The cysteine residue in the carboxyl-terminal domain of the m2 muscarinic acetylcholine receptor is not required for receptor-mediated inhibition of adenylate cyclase. Journal of Neurochemistry 57(6): 1873-1877, 1991

Pertussis toxin differentially alters cholinergic and adenosine receptor mediated inhibition of hormone activated adenylate cyclase in cardiac myocytes. FASEB Journal 2(4): ABSTRACT 2859, 1988

Muscarinic cholinergic receptor-mediated attenuation of adenylate cyclase activity in rat heart membranes. Journal of Cyclic Nucleotide and Protein Phosphorylation Research 10(2): 197-210, 1985

Mu opioid receptor mediated inhibition of beta adrenergic receptor sensitive adenylate cyclase in rat striatal neurons. Van Ree, J M , Et Al (Ed ) International Congress Series, No 914 New Leads in Opioid Research; International Narcotics Research Conference, Noordwijkerhout, Netherlands, July 8-13, Xxvii+391p Elsevier Science Publishers B V (Biomedical Division): Amsterdam, Netherlands; (Dist in The Usa And Canada By Elsevier Science Publishing Co , Inc : New York, New York) Illus 253-255, 1990

Muscarinic cholinergic agonists increase beta adrenergic receptor affinity for catecholamines and inhibit catecholamine stimulation of adenylate cyclase. Journal of Supramolecular Structure 7(Suppl. 2): 146, 1978

Heparin, dextran and trypan blue allosterically modulate M2 muscarinic receptor binding properties and interfere with receptor-mediated inhibition of adenylate cyclase. Journal of Pharmacology and Experimental Therapeutics 263(3): 910-917, 1992

Halothane disruption of alpha 2-adrenergic receptor-mediated inhibition of adenylate cyclase and receptor G-protein coupling in rat brain. Biochemical Pharmacology 39(1): 223-225, 1990

Muscarinic cholinergic-receptor stimulation of specific GTP hydrolysis related to adenylate cyclase activity in canine cardiac sarcolemma. Circulation Research 63(2): 340-350, 1988

Dissociation between muscarinic receptor-mediated inhibition of adenylate cyclase and autoreceptor inhibition of [3H] acetylcholine release in rat hippocampus. Journal of Pharmacology and Experimental Therapeutics 251(3): 1039-1044, 1989